Momenta Phama (MNTA) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Momenta (MNTA) Buy Rating Maintained at UBS (Earlier)
February 18, 2015 3:33 PM ESTUBS earlier maintained a Buy rating on Momenta Pharmaceuticals (NASDAQ: MNTA) and lowered its price target to $15.00 (from $18.00). The change follows Q4 results and comments during the call. Analyst Marc Goodman said his thesis hasn't changed.
"The FDA has said that there is nothing outstanding for the Copaxone application and mgt believes the... More
